TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.1 ILa | -0.50% |
|
+11.39% | +27.30% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 47.36 | 227.9 | 186.6 | 107.4 | 43.36 | 25.49 |
| Enterprise Value (EV) 1 | 49.09 | 242.5 | 192 | 113.8 | 60.86 | 38.91 |
| P/E ratio | -1.73 x | -15.5 x | -5.03 x | -3.42 x | -0.97 x | -0.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 8,617,143 x | 2,900,443 x | 879,594 x | 576,316 x |
| EV / Revenue | - | - | 8,863,230 x | 3,074,113 x | 1,234,605 x | 879,698 x |
| EV / EBITDA | - | -32,155,534 x | -9,651,033 x | -4,421,440 x | -7,262,809 x | -1,028,368 x |
| EV / FCF | -31.9 x | -14.8 x | -4.8 x | -6.55 x | -3.66 x | 1.86 x |
| FCF Yield | -3.13% | -6.74% | -20.8% | -15.3% | -27.3% | 53.8% |
| Price to Book | 439 x | 2.59 x | 1.35 x | 0.81 x | 0.46 x | 0.62 x |
| Nbr of stocks (in thousands) | 9,127 | 24,739 | 38,435 | 40,453 | 44,981 | 80,918 |
| Reference price 2 | 5.189 | 9.212 | 4.856 | 2.655 | 0.9640 | 0.3150 |
| Announcement Date | 3/27/19 | 4/30/20 | 3/30/21 | 3/30/22 | 3/28/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 21.66 | 37.03 | 49.3 | 44.23 |
| EBITDA | - | -7.542 | -19.89 | -25.75 | -8.38 | -37.83 |
| EBIT 1 | -1.123 | -7.548 | -32.2 | -42.9 | -26.36 | -93.23 |
| Operating Margin | - | - | -148.64% | -115.85% | -53.46% | -210.79% |
| Earnings before Tax (EBT) 1 | -21.17 | -10.93 | -35.02 | -34.03 | -49.14 | -93.99 |
| Net income 1 | -21.17 | -10.93 | -32.94 | -32.65 | -48.24 | -88.89 |
| Net margin | - | - | -152.09% | -88.17% | -97.85% | -200.97% |
| EPS 2 | -3.008 | -0.5960 | -0.9645 | -0.7772 | -0.9916 | -1.411 |
| Free Cash Flow 1 | -1.539 | -16.33 | -39.98 | -17.37 | -16.63 | 20.92 |
| FCF margin | - | - | -184.6% | -46.91% | -33.73% | 47.29% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/19 | 4/30/20 | 3/30/21 | 3/30/22 | 3/28/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.73 | 14.6 | 5.33 | 6.43 | 17.5 | 13.4 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -1.939 x | -0.268 x | -0.2498 x | -2.088 x | -0.3547 x |
| Free Cash Flow 1 | -1.54 | -16.3 | -40 | -17.4 | -16.6 | 20.9 |
| ROE (net income / shareholders' equity) | -13,793% | -21.9% | -29.5% | -24.3% | -37.7% | -125% |
| ROA (Net income/ Total Assets) | -17.7% | -5.8% | -11.5% | -13.9% | -9.5% | -49.9% |
| Assets 1 | 119.9 | 188.3 | 286.7 | 234.2 | 507.5 | 178 |
| Book Value Per Share 2 | 0.0100 | 3.560 | 3.590 | 3.260 | 2.110 | 0.5100 |
| Cash Flow per Share 2 | 0.2800 | 0.0700 | 0.2900 | 0.3000 | 0.0300 | 0.0800 |
| Capex 1 | 1.73 | 12.9 | 26.3 | 10.3 | 4.99 | 1.1 |
| Capex / Sales | - | - | 121.5% | 27.85% | 10.12% | 2.48% |
| Announcement Date | 3/27/19 | 4/30/20 | 3/30/21 | 3/30/22 | 3/28/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +27.30% | 8.74M | |
| +39.75% | 4.17B | |
| +148.03% | 2.33B | |
| +138.10% | 78.45M |
- Stock Market
- Equities
- TKUN Stock
- Financials Tikun Olam-Cannbit Pharmaceuticals Ltd